News
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
Moderna's Spikevax vaccine is the first to receive full approval for use in children aged 6 months to 11 years with a high-risk health issue.
StockStory.org on MSN1d
Why Moderna (MRNA) Stock Is Falling TodayShares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...
Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no longer be administered under an emergency use authorization.
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...
5d
Stocktwits on MSNModerna’s Covid Vaccine Gets Full FDA Approval For Use In Children 6 Months And OlderModerna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 ...
The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...
Fresh off of the heels of a shakeup at the CDC over vaccine recommendations, many Americans still question the necessity and ...
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results